Moreover, inhibition of FATP2 using lipofermata decreases ceramide synthesis, suggesting that some of the effects ascribed to FATP2 inhibition in various cancers (21, 22) may actually be mediated via the ceramide pathway. The gene discussed is SLC27A2; the disease is cancer.